by BENJAMIN WERNER CHRISTENSEN, translated by daniel pedersen
Obese patients can feel confused and stigmatized, and reaching out to men in particular can be difficult. On top of this, Danish pharmaceutical firm Novo Nordisk has recently been hit by big production issues.
There are plenty of challenges on the road to attaining the dream of treating obesity, first in the US and later in the rest of the world. Still, the rewards could be even greater, offering the opportunity to catapult Novo Nordisk into uncharted territory.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Rumored GN purchase unlikely but not impossible, say analysts
A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.
EMA begins analyzing Bavarian Nordic's vaccine against monkeypox
Prior to deciding on a shared European vaccine supply purchase, the European Medicines Agency has begun analyzing the Danish firm’s smallpox vaccine against monkeypox.
Bavarian Nordic eyes European monkeypox approval for smallpox vaccine
Bavarian Nordic’s smallpox vaccine, Jynneos, hasn’t yet been approved for monkeypox in Europe, a fact that hasn’t stopped countries there from lining up to secure vaccine supplies in light of the recent outbreak.
New CFO wants to shake things up at WSA
A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.
Chinese patent expiration dates draw closer for Novo Nordisk
In coming years, Novo Nordisk will take blows in the shape of several patents terminating on the second-biggest market for the firm, a Danish media reports.
System Sales Development Consultant - Investment Projects, Merck Millipore 
Senior QA Specialist 
Chemist for Incoming Materials in QC Department 
Nordic Medical Affairs Manager 
Clinical Trial Manager for development of in vitro diagnostics 
(Senior) Drug Substance Specialist 
KLIFO is looking for a Clinical Supply Manager for our Glostrup office 
Clinical Trial Manager 
Project Manager & Scrum Master 
Account Manager 
Biomarker Operations Lead 
Key Account Manager, Europe and Asia 
Senior Manager, Clinical Trial Budget 
Senior Chemical Safety Advisor 
Senior Project Manager (GMP - Life Science) 
Production Director